Clinical trials: Movement Abnormalities
Parkinson Disease
Estimates of the Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease
This study is double-blinded placebo controlled followed by an open-label extension placebo-to-active switch to estimate the efficacy of Talineuren.
- Trial name
- LIBRA (NCT06431971)
- Testing
- Talineuren
- Where
- 6 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- InnoMedica Schweiz AG
Parkinson Disease
An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.
The objective of this study is to evaluate the adhesion of the test product when compared to the reference product following a single transdermal application.
- Trial name
- NCT04183634
- Testing
- Rotigotine TTS (Test), Neupro (Reference)
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Sandoz
Parkinson Disease, Essential Tremor
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
- Conditions
- Parkinson Disease, Essential Tremor, Dystonia
- Trial name
- NCT03664609
- Testing
- Deep Brain Stimulation
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 5,000 people
- Sponsor
- Boston Scientific Corporation
Pantothenate Kinase-Associated Neurodegeneration
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
This study investigated whether fosmetpantotenate (RE-024), a phosphopantothenate replacement therapy, was safe and effective in treating participants with PKAN.
- Trial name
- PKAN (NCT03041116)
- Testing
- Fosmetpantotenate
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 84 people
- Sponsor
- Travere Therapeutics, Inc.
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Parkinson Disease
Evaluation of Clinical Progression in Patients With Motor Predominant Parkinson Disease.
The objective of this study is the longitudinal prospective clinical evaluation in patients with motor predominant PD; it will assess the individual disease progression (change) of the clinical and imaging parameters measured at…
- Trial name
- PARK001 (NCT03960242)
- Where
- 2 sites in France
- Volunteers
- 3 people
- Sponsor
- BrainEver
Parkinson Disease, Parkinson's Disease
REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study
Ropinirole Hydrochloride (ROP) was granted approval for the treatment of Parkinson's Disease (PD) on 20 October 2006. ROP is expected to be used for a long term in clinical practice.
- Trial name
- NCT00485069
- Testing
- ROP, ROP+L-Dopa
- Where
- 22 sites in Japan
- Volunteers
- 123 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.
The purpose of this study was to evaluate the differences in safety and efficacy between Parkinson's disease patients who either received transplantation of fetal porcine cells or placebo treatment.
- Trial name
- NCT00226460
- Testing
- Fetal porcine cells, Neurocell-PD
- Where
- United States
- Sponsor
- Genzyme, a Sanofi Company
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Progressive Supranuclear Palsy
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).
- Trial name
- NCT04658199
- Testing
- UCB0107 (bepranemab)
- Where
- 11 sites in Belgium, Germany and 2 more
- Volunteers
- 19 people
- Sponsor
- UCB Biopharma SRL
Parkinson's Disease, Movement Disorder Syndrome
A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of 40 mg per day of istradefylline (KW6002) as monotherapy in patients with Parkinson's disease.
- Trial name
- NCT00199433
- Testing
- Istradefylline (KW-6002)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Kyowa Kirin, Inc.
Parkinson´s Disease
Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations
The objective of this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in PD patients with motor fluctuations on levodopa therapy.
- Trial name
- NCT01736891
- Testing
- Rasagiline
- Where
- 8 sites in China
- Volunteers
- 268 people
- Sponsor
- Chongqing Fortune Pharmaceutical Co., Ltd.
Parkinson's Disease
Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease
The purpose of this study is to evaluate the safety and efficacy of KW-6500 when administered as long-term subcutaneous self-injections in Parkinson's disease patients with motor response complications on levodopa therapy.
- Trial name
- NCT00955318
- Testing
- KW-6500
- Where
- Japan
- Volunteers
- 58 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease
The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor ability within Parkinson's patients. vCR will be administered with a device called the VT Brain Glove.
- Trial name
- NCT04877015
- Testing
- Active Vibrotactile Coordinated Reset (vCR)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Synergic Medical Technologies, Inc.
Essential Tremor
EMBRACE Tremor BiFUS
This is a post-market (Phase IV) randomized, controlled, blinded, multicenter study with the aim to determine the added value of staged bilateral Exablate thalamotomy compared to a group of patients on previous unilateral…
- Trial name
- NCT06974916
- Testing
- Staged bilateral Exablate thalamotomy, Local standard medical treatment after previous Exablate unilateral thalamotomy.
- Where
- 13 sites in Finland, Germany and 5 more
- Volunteers
- 100 people
- Sponsor
- InSightec
Parkinson Disease (PD)
The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's disease.
- Trial name
- NCT07028632
- Testing
- Human Dopaminergic Progenitor Cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Parkinson's Disease
Assessing the Pharmacokinetics, Safety, Tolerability and Efficacy of Continuous Oral Levodopa Via the DopaFuse® Delivery System in Parkinson's Disease Patients
The purpose of this study is to evaluate whether the DopaFuse System can reduce the fluctuation of plasma levodopa levels compared to participants' standard intermittent doses of oral LD/CD tablets (background treatment).
- Trial name
- SCOL (NCT04778176)
- Testing
- continuous oral delivery of levodopa/carbidopa
- Where
- 5 sites in Italy, Luxembourg and 1 more
- Volunteers
- 17 people
- Sponsor
- SynAgile Corporation
Parkinson Disease
Observational Study of Pergolide Mesylate and Cardiac Valvulopathy
The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line…
- Trial name
- NCT00311532
- Where
- 14 sites in Belgium, France and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Parkinson's Disease, Hyperprolactinemia
The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events
To assess the association between cabergoline and other dopamine agonists (DAs), and symptomatic, diagnosed serious cardiopulmonary disorders, including: 1. Cardiac valve regurgitation 2.
- Trial name
- NCT01052948
- Testing
- Retrospective study-
- Volunteers
- 86,939 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.